Drug Trial Radar · NCT04676529
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Feb 18, 2021
Primary completion
Jul 9, 2025
Study completion Jul 9, 2025
Sponsor
- Lead sponsor
- SyntaraIndustry
- Sponsor type
- Industry
- First posted
- Dec 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.
Conditions
- Myelofibrosis
- Primary Myelofibrosis (PMF)
- Post- Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis
Interventions
PXS-5505Drug
PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Serious and Non-serious Adverse EventsTime frame: Day 0 to follow-up visit (28 -1/+7days post-Tx end) after up to 4wks Tx [escalation phase]; Day 0 to follow-up visit (28±3days post-Tx end) after up to 24wks Tx [expansion]); Day 0 to follow-up visit (28± 3days post-Tx end) after up to 52wks Tx [add-on].
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Comprehensive Cancer Center (UAB CCC)
Birmingham, Alabama
Novant Health Cancer Institute
Winston-Salem, North Carolina
The University of Texas MD Anderson Cancer Center
Houston, Texas
Liverpool Hospital
Liverpool, New South Wales, Australia
Ashford Cancer Centre Research
Adelaide, South Australia, Australia
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
One Clinical Research
Perth, Western Australia, Australia
The Perth Blood Institute
West Perth, Western Australia, Australia
National Cancer Center (Seoul Metro; northern)
Gyeonggi-do, South Korea
Seoul National University Hospital - Bundang
Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System- Haemat
Seoul, South Korea
Asan Medical Centre
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Inje University Busan Paik Hospital - Internal Medicine
Busan, Busan Gwang'yeogsi [Pusan-Kwan, South Korea
Keimyung University Dongsan Hospital
Daegu, Daegu Gwang'yeogsi [Taegu-Kwangyokshi], South Korea
Gachon University Gil Hospital
Incheon, Incheon Gwang'yeogsi [Inch'n-K, South Korea
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
China Medical University Hospital - Internal Medicine - Taichung
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital - Hematology And Oncology
Taipei, Taiwan
Chang Gung Medical Foundation - ChiaYi Chang Gung Memorial Hospital - Hematology and Oncology
Chiayi City, Chiayi, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.